Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. .
   PubMed Web of Science ®Google Scholar
• Tanaka T, Yang M, Froemming AT, et al. Current imaging techniques for and imaging spectrum of prostate cancer recurrence and metastasis: a pictorial review. Radiographics. 2020;40(3):709–726. .
   PubMed Web of Science ®Google Scholar
• Trabulsi EJ, Rumble RB, Jadvar H, et al., Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 38(17): 1963–1996. 2020. .
   PubMed Web of Science ®Google Scholar
• Metser U, Chua S, Ho B, et al. The contribution of multiparametric pelvic and whole-body mri to interpretation of18 f-fluoromethylcholine or 68 Ga-HBED-CC PSMA-11 PET/CT in patients with biochemical failure after radical prostatectomy. J Nucl Med. 2019;60(9):1253–1258. .
   PubMed Web of Science ®Google Scholar
• Lindenberg L, Choyke P, Dahut W. Prostate cancer imaging with novel PET tracers. Curr Urol Rep. 2016;17(3):18.
   PubMed Web of Science ®Google Scholar
• von Eyben FE, Kairemo K. Acquisition with (11)C-choline and (18)F-fluorocholine PET/CT for patients with biochemical recurrence of prostate cancer: a systematic review and meta-analysis. Ann Nucl Med. 2016;30(6):385–392.
   PubMed Web of Science ®Google Scholar
• Bauman G, Belhocine T, Kovacs M, et al. 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis. 2012;15(1):45–55. .
   PubMed Web of Science ®Google Scholar
• David Crawford E, Koo PJ, Shore N, et al. A clinician’s guide to next generation imaging in patients with advanced prostate cancer (RADAR III). J Urol. 2019;201(4):682–692. .
   PubMed Web of Science ®Google Scholar
• Evans JD, Jethwa KR, Ost P, et al., Prostate cancer–specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol. 8(1): 28–39. 2018. .
   PubMed Web of Science ®Google Scholar
• Maurer T, Eiber M, Schwaiger M, et al. Current use of PSMA-PET in prostate cancer management. Nat Rev Urol. 2016;13(4):226–235. .
   PubMed Web of Science ®Google Scholar
• Poulsen MH, Petersen H, Høilund-Carlsen PF, et al. Spine metastases in prostate cancer: comparison of technetium-99m-MDP whole-body bone scintigraphy, [18F]choline positron emission tomography(PET)/computed tomography (CT) and [18F]NaF PET/CT. BJU Int. 2014;114(6):818–823. .
   PubMed Web of Science ®Google Scholar
• Jadvar H, Desai B, Ji L, et al. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012;37(7):637–643. .
   PubMed Web of Science ®Google Scholar
• Wei J, Zhu H, Liao X. Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment. Oncotarget. 2018;9(18):14630–14641.
   PubMedGoogle Scholar
• Ghosh A, Heston WDW. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem. 2004;91(3):528–539.
   PubMed Web of Science ®Google Scholar
• Rosenthal SA, Haseman MK, Polascik TJ. Utility of capromab pendetide (ProstaScint) imaging in the management of prostate cancer. Tech Urol. 2001;7(1):27–37.
   PubMedGoogle Scholar
• Afshar-Oromieh A, Zechmann CM, Malcher A, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20. .
   PubMed Web of Science ®Google Scholar
• Afshar-Oromieh A, Avtzi E, Giesel FL, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209. .
   PubMed Web of Science ®Google Scholar
• National Library of Medicine (US), National center for biotechnology information. pubmed [internet]. 2020. Available from: https://pubmed.ncbi.nlm.nih.gov/.
   Google Scholar
• Perera M, Papa N, Roberts M, et al., Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-. Eur Urol. 77(4): 403–417. 2020. .
   PubMed Web of Science ®Google Scholar
• Treglia G, Annunziata S, Pizzuto DA, et al. Detection rate of18 F-labeled PSMA PET/CT in biochemical recurrent prostate cancer: a systematic review and a meta-analysis. Cancers (Basel). 2019;11(5):1–14. .
   Web of Science ®Google Scholar
• Han S, Woo S, Kim YJ, et al., Impact of 68Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis. Eur Urol. 74(2): 179–190. 2018. .
   PubMed Web of Science ®Google Scholar
• Calais J, Ceci F, Eiber M, et al. 18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial. Lancet Oncol. 2019;20(9):1286–1294. .
   PubMed Web of Science ®Google Scholar
• Tan N, Oyoyo U, Bavadian N, et al. PSMA-targeted radiotracers versus18 f fluciclovine for the detection of prostate cancer biochemical recurrence after definitive therapy: a systematic review and meta-analysis. Radiology. 2020;296(1):44–55. .
   PubMed Web of Science ®Google Scholar
• Treglia G, Pereira Mestre R, Ferrari M, et al. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. Am J Nucl Med Mol Imaging. 2019;9(2):127–139.
   PubMed Web of Science ®Google Scholar
• Hofman MS, Lawrentschuk N, Francis RJ, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet (London, England). 2020;395(10231):1208–1216. .
   PubMed Web of Science ®Google Scholar
• Fendler WP, Calais J, Eiber M, et al., Assessment of 68 Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer. JAMA Oncol. 5(6): 856–863. 2019. .
   PubMed Web of Science ®Google Scholar
• Morris MJ, Carroll PR, Saperstein L, et al. Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): results from a phase III, prospective, multicenter study (CONDOR). am soc clin oncol. J clin oncol. 2020;38(15_suppl). 10.1200/JCO.2020.38.15_suppl.5501.
   Web of Science ®Google Scholar
• Pereira Mestre R, Treglia G, Ferrari M, et al. Correlation between PSA kinetics and PSMA-PET in prostate cancer restaging: a meta-analysis. Eur J Clin Invest. 2019;49(3):1–12. .
   Web of Science ®Google Scholar
• Dietlein F, Kobe C, Neubauer S, et al. PSA-stratified performance of 18 F- and 68 Ga-PSMA PET in patients with biochemical recurrence of prostate cancer. J Nucl Med. 2017;58(6):947–952. .
   PubMed Web of Science ®Google Scholar
• Dietlein M, Kobe C, Kuhnert G, et al. Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015;17(4):575–584. .
   PubMed Web of Science ®Google Scholar
• Foley RW, Redman SL, Graham RN, et al. Fluorine-18 labelled prostate-specific membrane antigen (PSMA)-1007 positron-emission tomography-computed tomography: normal patterns, pearls, and pitfalls. Clin Radiol. 2020. 10.1016/j.crad.2020.06.031.
   Web of Science ®Google Scholar
• Rauscher I, Krönke M, König M, et al. Matched-pair comparison of 68 Ga-PSMA-11 PET/CT and 18 F-PSMA-1007 PET/CT: frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy. J Nucl Med. 2020;61(1):51–57. .
   PubMed Web of Science ®Google Scholar
• Evangelista L, Zattoni F, Cassarino G, et al. PET/MRI in prostate cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2020. 10.1007/s00259-020-05025-0.
   PubMedGoogle Scholar
• Rousseau E, Wilson D, Lacroix-Poisson F, et al. A prospective study on 18 F-DCFPyL PSMA PET/CT imaging in biochemical recurrence of prostate cancer. J Nucl Med. 2019;60(11):1587–1593. .
   PubMed Web of Science ®Google Scholar
• Rowe S, Gorin M, Pienta K, et al. Results from the OSPREY trial: a PrOspective phase 2/3 multi-center study of 18F-DCFPyL PET/CT imaging in patients with prostate cancer - examination of diagnostic accuracY. J Nucl Med. 2019;60:586.
   Web of Science ®Google Scholar
• Schiller K, Stöhrer L, Düsberg M, et al. PSMA-PET/CT–based lymph node atlas for prostate cancer patients recurring after primary treatment: clinical implications for salvage radiation therapy. Eur Urol Oncol. 2020. 10.1016/j.euo.2020.04.004
   PubMedGoogle Scholar
• Hall WA, Paulson E, Davis BJ, et al. NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and post-operative prostate cancer. Int J Radiat Oncol Biol Phys. 2020. 10.1016/j.ijrobp.2020.07.2198.
   Web of Science ®Google Scholar
• Shipley WU, Seiferheld W, Lukka HR, et al. Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med. 2017;376(5):417–428. .
   PubMed Web of Science ®Google Scholar
• Crook JM, O’Callaghan CJ, Duncan G, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012;367(10):895–903. .
   PubMed Web of Science ®Google Scholar
• Carrie C, Magné N, Burban-Provost P, et al. Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. Lancet Oncol. 2019;20(12):1740–1749. .
   PubMed Web of Science ®Google Scholar
• Schmidkonz C, Cordes M, Schmidt D, et al. 68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(11):1862–1872. .
   PubMed Web of Science ®Google Scholar
• Lee J, Sato MM, Coel MN, et al. Prediction of PSA progression in castration-resistant prostate cancer based on treatment-associated change in tumor burden quantified by 18F-Fluorocholine PET/CT. J Nucl Med. 2016;57(7):1058–1064. .
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol. 2009;181(3):956–962. .
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bartkowiak D, Bottke D, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014;66(2):243–250. .
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Tombal B, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet (London, England). 2012;380(9858):2018–2027. .
   PubMed Web of Science ®Google Scholar
• Philippou Y, Parker RA, Volanis D, et al. Comparative oncologic and toxicity outcomes of salvage radical prostatectomy versus nonsurgical therapies for radiorecurrent prostate cancer: a meta-regression analysis. Eur Urol Focus. 2016;2(2):158–171. .
   PubMedGoogle Scholar
• Baty M, Créhange G, Pasquier D, et al. Salvage reirradiation for local prostate cancer recurrence after radiation therapy. For Who? When? How? Cancer Radiother. 2019;23(6–7):541–558. .
   PubMed Web of Science ®Google Scholar
• Corkum MT, Mendez LC, Chin J, et al. A novel salvage option for local failure in prostate cancer, reirradiation using external beam or stereotactic radiation therapy: systematic review and meta-analysis. Adv Radiat Oncol. 2020;5(1):1–13. .
   PubMedGoogle Scholar
• Parker CC, Clarke NW, Cook AD, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet. 2020;6736:1–9.
   Google Scholar
• Kneebone A, Fraser-Browne C, Duchesne GM, et al. Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. Lancet Oncol. 2020;21(10):1331–1340. .
   PubMed Web of Science ®Google Scholar
• Sargos P, Chabaud S, Latorzeff I, et al. Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. Lancet Oncol. 2020;21(10):1341–1352. .
   PubMed Web of Science ®Google Scholar
• Vale CL, Fisher D, Kneebone A, et al. Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet. 2020;6736:1–3.
   Google Scholar
• Jani A, Schuster D. Initial report of a randomized trial comparing conventional- vs conventional plus fluciclovine (18F) PET/CT imaging-guided post-prostatectomy radiotherapy for prostate cancer. Am Soc Radiat Oncol. 2020;108(5): 1397.
   Google Scholar
• Calais J, Czernin J, Fendler WP, et al. Randomized prospective phase III trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT]. BMC Cancer. 2019;19(1):18. .
   PubMedGoogle Scholar
• Calais J, Armstrong WR, Kishan AU, et al. Impact of PSMA PET/CT on SRT planning: preliminary results from a randomized phase 3 trial. Int J Radiat Oncol Biol Phys. 2020;108(3):859–860. .
   Web of Science ®Google Scholar
• Emmett L, Tang R, Nandurkar R, et al., 3-year freedom from progression after 68 Ga-PSMA PET/CT–triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial. J Nucl Med. 61(6): 866–872. 2020. .
   PubMed Web of Science ®Google Scholar
• Sonni I, Eiber M, Fendler WP, et al. Impact of 68 Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single center study. J Nucl Med. 2020;61(8):119.237602. jnumed. .
   PubMed Web of Science ®Google Scholar
• Roach PJ, Francis R, Emmett L, et al. The Impact of 68 Ga-PSMA PET/CT on management intent in prostate cancer: results of an australian prospective multicenter study. J Nucl Med. 2018;59(1):82–88. .
   PubMed Web of Science ®Google Scholar
• Emmett L, Metser U, Bauman G, et al. Prospective, multisite, international comparison of 18 f-fluoromethylcholine PET/CT, multiparametric MRI, and 68 Ga-HBED-CC PSMA-11 PET/CT in men with high-risk features and biochemical failure after radical prostatectomy: clinical performance and patient Outcomes. J Nucl Med. 2019;60(6):794–800. .
   PubMed Web of Science ®Google Scholar
• Pollack A, Karrison TG, Balogh AG, et al. Short term androgen deprivation therapy without or with pelvic lymph node treatment added to prostate bed only salvage radiotherapy: the nrg oncology/rtog 0534 spport trial. Int J Radiat Oncol. 2018;102(5):1605. .
   Web of Science ®Google Scholar
• Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974. .
   PubMed Web of Science ®Google Scholar
• Oh J, Tyldesley S, Pai H, et al. An updated analysis of survival endpoints for ascende-rt, a randomized trial comparing a lowdose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Can Assoc Radiat Oncol. 2020;p.s9.
   Google Scholar
• Einspieler I, Rauscher I, Düwel C, et al. Detection efficacy of hybrid 68 Ga-PSMA Ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by phoenix criteria. J Nucl Med. 2017;58(7):1081–1087. .
   PubMed Web of Science ®Google Scholar
• Meredith G, Wong D, Yaxley J, et al. The use of 68Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int. 2016;118:49–55.
   PubMed Web of Science ®Google Scholar
• Liu W, Zukotynski K, Emmett L, et al., A prospective study of 18F-DCFPyL PSMA PET/CT restaging in recurrent prostate cancer following primary external beam radiotherapy or brachytherapy. Int J Radiat Oncol Biol Phys. 106(3): 546–555. 2020. .
   PubMed Web of Science ®Google Scholar
• Gupta SK, Watson T, Denham J, et al. Prostate-specific membrane antigen positron emission tomography–computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning. Int J Radiat Oncol Biol Phys. 2017;99(3):701–709. .
   PubMed Web of Science ®Google Scholar
• Rodgers J, Crook J, Thomas P, et al. NCI salvage low dose rate prostate brachytherapy: clinical outcomes of a phase ii trial for local recurrence after external beam radiotherapy (NRG/RTOG 0526). Can Assoc Radiat Oncol. 2020: S8.
   Google Scholar
• Liu W, Zukotynski K, Emmett L, et al. Utilization of salvage and systemic therapies for recurrent prostate cancer as a result of 18F-DCFPyL PET/CT Restaging. Adv Radiat Oncol. 2020;5(1):1–7.
   PubMedGoogle Scholar
• van Son MJ, Peters M, Moerland MA, et al. MRI-guided ultrafocal salvage high-dose-rate brachytherapy for localized radiorecurrent prostate cancer: updated results of 50 patients. Int J Radiat Oncol Biol Phys. 2020;107(1):126–135. .
   PubMed Web of Science ®Google Scholar
• Bergamin S, Eade T, Kneebone A, et al. Interim results of a prospective prostate-specific membrane antigen-directed focal stereotactic reirradiation trial for locally recurrent prostate cancer. Int J Radiat Oncol Biol Phys. 2020. 10.1016/j.ijrobp.2020.07.014.
   PubMedGoogle Scholar
• Lépinoy A, Silva YE, Martin E, et al. Salvage extended field or involved field nodal irradiation in 18F-fluorocholine PET/CT oligorecurrent nodal failures from prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(1):40–48. .
   PubMed Web of Science ®Google Scholar
• De Bleser E, Jereczek-Fossa BA, Pasquier D, et al. Metastasis-directed therapy in treating nodal oligorecurrent prostate cancer: a multi-institutional analysis comparing the outcome and toxicity of stereotactic body radiotherapy and elective nodal radiotherapy. Eur Urol. 2019;76(6):732–739. .
   PubMed Web of Science ®Google Scholar
• Bravi CA, Fossati N, Gandaglia G, et al. Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought. Eur Urol. 2020;78(5): 661–669.
   Web of Science ®Google Scholar
• Steuber T, Jilg C, Tennstedt P, et al., Standard of care versus metastases-directed therapy for pet-detected nodal oligorecurrent prostate cancer following multimodality treatment: a multi-institutional case-control study. Eur Urol Focus. 5(6): 1007–1013. 2019. .
   PubMedGoogle Scholar
• Achard V, Bottero M, Rouzaud M, et al., Radiotherapy treatment volumes for oligorecurrent nodal prostate cancer: a systematic review. Acta Oncol. 59(10): 1224–1234. 2020. .
   PubMed Web of Science ®Google Scholar
• Luiting HB, van Leeuwen PJ, Busstra MB, et al. Use of gallium-68 prostate-specific membrane antigen positron-emission tomography for detecting lymph node metastases in primary and recurrent prostate cancer and location of recurrence after radical prostatectomy: an overview of the current literature. BJU Int. 2020;125(2):206–214. .
   PubMed Web of Science ®Google Scholar
• Van Leeuwen PJ, Stricker P, Hruby G, et al. 68 Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732–739. .
   PubMed Web of Science ®Google Scholar
• Budäus L, Leyh-Bannurah SR, Salomon G, et al. Initial experience of 68Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol. 2016;69(3):393–396. .
   PubMed Web of Science ®Google Scholar
• Öbek C, Doğanca T, Demirci E, et al. The accuracy of 68Ga-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(11):1806–1812. .
   PubMed Web of Science ®Google Scholar
• Hellman S, Weichselbaum, R. Oligometastases.Clin Oncol J. 1995;13:8–10. 1
   Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019;393(10185):2051–2058. .
   PubMed Web of Science ®Google Scholar
• Ost P, Reynders D, Decaestecker K, et al., Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 36(5): 446–453. 2018. .
   PubMed Web of Science ®Google Scholar
• Gomez DR, Blumenschein GR, Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17(12):1672–1682. .
   PubMed Web of Science ®Google Scholar
• Iyengar P, Wardak Z, Gerber DE, et al. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018;4(1):e173501. .
   PubMed Web of Science ®Google Scholar
• Phillips R, Shi WY, Deek M, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659. .
   PubMed Web of Science ®Google Scholar
• Palma DA, Olson R, Harrow S, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase ii randomized trial. J Clin Oncol. 2020;38(25):2830–2838. .
   PubMed Web of Science ®Google Scholar
• Guckenberger M, Lievens Y, Bouma AB, et al. Characterisation and classification of oligometastatic disease: a european society for radiotherapy and oncology and european organisation for research and treatment of cancer consensus recommendation. Lancet Oncol. 2020;21(1):e18–e28. .
   PubMed Web of Science ®Google Scholar
• Siva S, Bressel M, Murphy DG, et al., Stereotactic abative body radiotherapy (SABR) for oligometastatic prostate cancer: a prospective clinical trial. Eur Urol. 74(4): 455–462. 2018. .
   PubMed Web of Science ®Google Scholar
• Gundem G, Van Loo P, Kremeyer B, et al. The evolutionary history of lethal metastatic prostate cancer. Nature. 2015;520(7547):353–357. .
   PubMed Web of Science ®Google Scholar
• Xu MJ, Kornberg Z, Gadzinski AJ, et al. Genomic risk predicts molecular imaging-detected metastatic nodal disease in prostate cancer. Eur Urol Oncol. 2019;2(6):685–690. .
   PubMed Web of Science ®Google Scholar
• Li GJ, Arifin AJ, Al-Shafa F, et al. A review of ongoing trials of stereotactic ablative radiotherapy for oligometastatic disease in the context of new consensus definitions. Ann Palliat Med. 2020. 10.21037/apm-20-847.
   Web of Science ®Google Scholar
• Gravis G, Boher J, Chen Y, et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 Studies. Eur Urol. 2018;73(6):847–855.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang T, Ma Z, et al. Systemic management for nonmetastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Am J Clin Oncol. 2020;43(4):288–297.
   PubMed Web of Science ®Google Scholar
• Zukotynski K, Rowe SP, Valliant J, et al. 18F-DCFPyL PET/CT in Castration-Cancer RP (CRPC): Imaging results prior to and following abiraterone or enzalutemide therapy. 65th SNMMI Annu Meet Philadelphia, PA. 2018.
   Google Scholar
• Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3. J Clin Oncol. 2016;34(12):1402–1418.
   PubMed Web of Science ®Google Scholar
• Iravani A, Violet J, Azad A, et al. Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies. Prostate Cancer Prostatic Dis. 2020;23(1):38–52.
   PubMed Web of Science ®Google Scholar
• Sun M, Niaz MO, Nelson A, et al. Review of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Cureus. 2020;12:10–17.
   Web of Science ®Google Scholar
• Hofman MS, Violet J, Hicks RJ, et al., [177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 19(6): 825–833. 2018. .
   PubMed Web of Science ®Google Scholar
• Yadav MP, Ballal S, Bal C, et al. Efficacy and safety of 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients. Clin Nucl Med. 2020;45(1):19–31. .
   PubMed Web of Science ®Google Scholar
• Hofman MS, Emmett L, Sandhu SK, et al., TheraP: a randomised phase II trial of 177 Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC) progressing after docetaxel: initial results (ANZUP protocol 1603). J Clin Oncol. 38(15_suppl): 5500. 2020.
   Web of Science ®Google Scholar
• Cornford P, RCN VDB, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. part ii-2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol. 2020;79(2): 263–282.
   Google Scholar